851091-96-8

Upstream product

• 865839-06-1 C₁₇H₂₉N₃O₅ 
• 2486-71-7 4-amino-3-chlorobenzoic acid 
• 62965-10-0 (S)-N-carbobenzoxy-tert-butylleucine 
• 374773-69-0 1-[2-(4-amino-3-chlorobenzoylamino)-3,3-dimethylbutyryl]pyrrolidine-2-carboxylic acid tert-butyl ester 
• 410079-22-0 (4S_. 5R)-4-Amino-5-ethoxy-dihydro-furan-2-one 
• 374773-70-3 (S)-1-((S)-2-(4-amino-3-chlorobenzamido)-3,3-dimethylbutanoyl)pyrrolidine-2-carboxylic acid 
• 1230628-85-9 C₁₅H₂₈N₂O₃ 
• 220184-67-8 ((2R,3S)-2-ethoxy-5-oxo-tetrahydro-furan-3-yl)-carbamic acid allyl ester 
• 20859-02-3 L-tert-Leucine 
• 409369-63-7 3-amino-4-oxo-butanoic acid β-tert-butyl ester diethyl acetal 
• 2812-46-6 proline tert-butyl ester 
• 132684-60-7 (S)-2-((((9H-fluoren-9-yl)methoxy)carbonyl)amino)-3,3-dimethylbutanoic acid 

Relevant academic research and scientific papers

Caspase inhibitors

A compound, or a pharmaceutically acceptable salt or ester thereof, of formula I: X—W wherein X is a caspase-selective structure and W has the structure of —NH—CH(Y)(Z) wherein Y is

Prodrug of an ice inhibitor

This invention describes an ICE inhibitor prodrug (I) having good bioavailability. Compound I is useful for treating IL-1 mediated diseases such as rheumatoid arthritis, inflammatory bowel disease, Crohn's disease, ulcerative colitis, inflammatory periton

A highly potent and selective caspase 1 inhibitor that utilizes a key 3-cyanopropanoic acid moiety

Herein, we examine the potential of a nitrile-containing propionic acid moiety as an electrophile for covalent attack by the active-site cysteine residue of caspase 1. The syntheses of several cyanopropanate-containing small molecules based on the optimiz

Development of a novel Pd-catalyzed N-acyl vinylogous carbamate synthesis for the key intermediate of ICE inhibitor VX-765

(Chemical Equation Presented) A novel Pd-catalyzed coupling of Cbz-protected proline amide with 4-bromo-5-ethoxyfuran-2(5H)-one was developed for the synthesis of the P1-P2 unit (5) of VX-765. The process afforded quantitative coupling in the presence of water, providing a 1:1 mixture of 5 and its ethoxy epimer epi-5. Compound 5 was isolated as a single diastereomer via fractional crystallization, which was stereoselectively converted to 17 via hydrogenation, and subsequently transformed to VX-765. Nine examples of the Pd coupling are presented with yields ranging from 76-98%.

PROCESSES AND INTERMEDIATES

The invention relates to processes and compounds useful for producing modified aspartic acid derivatives, such as aspartic acid aldehyde moieties. Aspartic acid derivatives are useful for preparing caspase inhibitors and/or prodrugs thereof.

Process and intermediates for making substituted aspartic acid acetals

Disclosed herein is a method for making compounds that are useful as caspase inhibitor prodrugs of formula I: wherein R1 is an optionally substituted group selected from an aliphatic group, aralkyl group, heterocyclylalkyl group or aryl group,

Prodrug of an ice inhibitor

This invention describes an ICE inhibitor prodrug (I) having good bioavailability. Compound I is useful for treating IL-1 mediated diseases such as rheumatoid arthritis, inflammatory bowel disease, Crohn's disease, ulcerative colitis, inflammatory periton